<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/">
<rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6838">
    <dcterms:title><![CDATA[<strong>The acute inflammatory potential of particles from the Echinococcus granulosus laminated layer is moderated by its calcium inositol Hexakisphosphate component.</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[EQUINOCOCOSIS QUISTICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[ECHINOCOCCUS GRANULOSUS]]></dcterms:subject>
    <dcterms:subject><![CDATA[INFLAMACI&Oacute;N]]></dcterms:subject>
    <dcterms:subject><![CDATA[MUCINAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[INOSITOL]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2024]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Cystic echinococcosis is caused by the tissue-dwelling larva (hydatid) of Echinococcus granulosus sensu lato. A salient feature is that this larva is protected by the acellular laminated layer (LL). As the parasite grows, the LL sheds abundant particles that can accumulate in the parasite's vicinity. The potential of LL particles to induce inflammation in vivo has not been specifically analysed. It is not known how each of its two major components, namely highly glycosylated mucins and calcium inositol hexakisphosphate (InsP6) deposits, impacts inflammation induced by the LL as a whole. In this work, we show that LL particles injected intraperitoneally cause infiltration of eosinophils, neutrophils and monocytes/macrophages as well as the disappearance of resident (large peritoneal) macrophages. Strikingly, the absence of calcium InsP6 enhanced the recruitment of all the inflammatory cell types analysed. In contrast, oxidation of the mucin carbohydrates caused decreased recruitment of neutrophils. The carbohydrate-oxidised particles caused cell influx nonetheless, which may be explained by possible receptor-independent effects of LL particles on innate immune cells, as suggested by previous works from our group. In summary, LL particles can induce acute inflammatory cell recruitment partly dependent on its mucin glycans, and this recruitment is attenuated by the calcium InsP6 component.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Grezzi, Leticia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Gonz&aacute;lez, Carlos</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>D&iacute;az, Alvaro</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Casaravilla, Cecilia</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Parasite Immunology v. 46, n&deg; 5, 2024. -- e13040]]></dcterms:source>
    <dcterms:publisher><![CDATA[Wiley]]></dcterms:publisher>
    <dcterms:date><![CDATA[2024]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong>&nbsp;de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[6 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.1111/pim.13040]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6379">
    <dcterms:title><![CDATA[<strong>In Vitro bioaccessibility of bioactive compounds from citrus pomaces and orange pomace biscuits&nbsp;</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[AMILASAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[INFLAMACION]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTIOXIDANTES]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIOACCESIBILIDAD]]></dcterms:subject>
    <dcterms:subject><![CDATA[CITRICOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[DIABETES]]></dcterms:subject>
    <dcterms:subject><![CDATA[GLUCOSIDASA]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANALISIS SENSORIAL]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2021]]></dcterms:subject>
    <dcterms:abstract><![CDATA[<p>The present investigation aimed to provide novel information on the chemical composition and in vitro bioaccessibility of bioactive compounds from raw citrus pomaces (mandarin varieties Clemenule and Ortanique and orange varieties Navel and Valencia). The effects of the baking process on their bioaccessibility was also assessed. Samples of pomaces and biscuits containing them as an ingredient were digested, mimicking the human enzymatic oral gastrointestinal digestion process, and the composition of the digests were analyzed. UHPLC-MS/MS results of the citrus pomaces flavonoid<br />composition showed nobiletin, hesperidin/neohesperidin, tangeretin, heptamethoxyflavone, tetramethylscutellarein, and naringin/narirutin. The analysis of the digests indicated the bioaccessibility of compounds possessing antioxidant [6.6&ndash;11.0 mg GAE/g digest, 65.5&ndash;97.1 mol Trolox Equivalents<br />(TE)/g digest, and 135.5&ndash;214.8 mol TE/g digest for total phenol content (TPC), ABTS, and ORAC-FL methods, respectively; significant reduction (p &lt; 0.05) in Reactive Oxygen Species (ROS) formation under tert-butyl hydroperoxide (1 mM)-induced conditions in IEC-6 and CCD-18Co cells when pre-treated with concentrations 5&ndash;25 g/mL of the digests], anti-inflammatory [significant reduction (p &lt; 0.05) in nitric oxide (NO) production in lipopolysaccharide (LPS)-induced RAW264.7 macrophages], and antidiabetic (IC50 3.97&ndash;11.42 mg/mL and 58.04&ndash;105.68 mg/mL for -glucosidase and -amylase inhibition capacities) properties in the citrus pomaces under study. In addition, orange pomace biscuits with the nutrition claims &ldquo;no-added sugars&rdquo; and &ldquo;source of fiber&rdquo;, as well as those with good sensory quality (6.9&ndash;6.7, scale 1&ndash;9) and potential health promoting properties, were<br />obtained. In conclusion, the results supported the feasibility of citrus pomace as a natural sustainable source of health-promoting compounds such as flavonoids. Unfractionated orange pomace may be employed as a functional food ingredient for reducing the risk of pathophysiological processes linked to oxidative stress, inflammation, and carbohydrate metabolism, such as diabetes, among others.</p>]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<a href="https://exportcvuy.anii.org.uy/cv/?48a71d2e5134808569068d2724790a8aea8b2933a5fec257ee3e4e79c698c53217947faea852f59905ef92c97b0830d7d801d00a336d676bae44ed023b6adffa" target="_blank"><strong>Fern&aacute;ndez Fern&aacute;ndez, Adriana Maite</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://exportcvuy.anii.org.uy/cv/?5a728c53379ba11edafc6029548ce29d65b0e495e64982b067a2707fc9d44e90fa33fc21f214f2d552656809bf896fdbcfece552c850bab35f4d18fc3812ebd9" target="_blank"><strong>Dellacassa, Eduardo</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Nardin, Tiziana</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Larcher, Roberto</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>G&aacute;mbaro, Adriana</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://exportcvuy.anii.org.uy/cv/?7c64fd0475a2077f15b2edfba26c864ffb58e74137469e728a10a1e9f597797565a168ad79a66a0e079ca1f99d19153126e8d3094144e8ab95c1a3e8ff5e8111" target="_blank"><strong>Medrano Fernandez, Alejandra</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>del Castillo, Mar&iacute;a Dolores</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Molecules&nbsp;v. 26. n&deg; 12, 2021. --pp. 1-18. -- e3480]]></dcterms:source>
    <dcterms:publisher><![CDATA[MDPI]]></dcterms:publisher>
    <dcterms:date><![CDATA[2021]]></dcterms:date>
    <dcterms:rights><![CDATA[<p dir="ltr"><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p dir="ltr"><span>(Por favor lea este aviso antes de abrir los documentos u objetos)</span></p>
<p dir="ltr"><strong>La legislaci&oacute;n uruguaya protege el derechode autor</strong><span>&nbsp;sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</span></p>
<span id="docs-internal-guid-9d2103f7-7fff-c813-00c7-2528fd4891ff"><strong>ADVERTENCIA:</strong><span>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</span></span>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[<span id="docs-internal-guid-6dc1c3f1-7fff-844d-e8e2-b26a30d02e9d"><span>10.3390/molecules26123480&nbsp; </span></span>]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6320">
    <dcterms:title><![CDATA[<strong>A novel nitroalkene vitamin E analogue inhibits the NLRP3 inflammasome and protects against inflammation and glucose intolerance triggered by obesity</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[INFALAMACION]]></dcterms:subject>
    <dcterms:subject><![CDATA[INTOLERANCIA A LA GLUCOSA]]></dcterms:subject>
    <dcterms:subject><![CDATA[INFLAMASOMAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[NITROALQUENOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[OBESIDAD]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2021]]></dcterms:subject>
    <dcterms:abstract><![CDATA[<p>Chronic metabolic diseases, like obesity, type II diabetes and atherosclerosis often involve a low-grade and sterile systemic inflammatory state, in which activation of the pro-inflammatory transcription factor NF-kB and the NLRP3 inflammasome play a major role. It is well established that genetic inhibition of the NLRP3 inflammasome ameliorates acute and chronic inflammation. Indeed, accumulating experimental evidences in murine models and also in humans suggest that inhibition of the NLRP3 inflammasome might be a suitable approach to tackle the deleterious effects of chronic metabolic diseases. In this work, we explored our previously synthesized nitroalkene-Trolox&trade; derivative named NATx0, as a non-conventional anti-inflammatory strategy to treat chronic inflammatory diseases, such as obesity-induced glucose intolerance. We found that NATx0 inhibited NF-kB nuclear translocation and pro-inflammatory gene expression in macrophages in vitro. In addition, treatment with NATx0 prevented NLRP3 inflammasome activation after LPS/ATP stimulation in macrophages in vitro. When tested acutely in vivo, NATx0 inhibited neutrophil recruitment in zebrafish larvae, and also diminished IL- 1&beta; production after LPS challenge in mice. Finally, when NATx0 was administered chronically to diet-induced obese mice, it decreased muscle tissue inflammation and glucose intolerance, leading to improved glucose homeostasis. In conclusion, we propose that this novel nitroalkene-Trolox derivative is a suitable tool to tackle acute and chronic inflammation in vitro and in vivo mainly due to inhibition of NF-kB/NLRP3 activation.</p>]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Dapueto, Rosina</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Galliussi, Germ&aacute;n</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Kamaid, Andr&eacute;s</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Bresque, Mariana</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Batthy&aacute;ny, Carlos</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://exportcvuy.anii.org.uy/cv/?703719349e39a99eec152464e8f08cd9f9f9fb2286d6f029200c1c7564ce5a7999708965c91b1824d25369d381afc497aa17eb07cce0d5f2e99cf322b898407f" target="_blank"><strong>L&oacute;pez, Gloria V.</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Escande, Carlos</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Rodr&iacute;guez Duarte, Jorge.<br /></strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Redox Biology&nbsp;v. 39, 2021. --p. 1-10. -- e101833]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2021]]></dcterms:date>
    <dcterms:rights><![CDATA[<strong>Informaci&oacute;n sobre Derechos de Autor</strong>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya&nbsp;protege el derecho de autor</strong> sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA</strong>&nbsp;- La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[<a class="doi" title="Persistent link using digital object identifier" href="https://doi.org/10.1016/j.redox.2020.101833" rel="noreferrer noopener" target="_blank">https://doi.org/10.1016/j.redox.2020.101833</a>]]></dcterms:identifier>
</rdf:Description></rdf:RDF>
